2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B1582A
    Canrenoate potassium 2181-04-6 99.89%
    Canrenoate (Aldadiene) potassium, a proagent that releases canrenone, is a potent, competitive mineralocorticoid receptor (aldosterone receptor) antagonist. Potassium canrenoate, as a diuretic, is used for the research of hypertension.
    Canrenoate potassium
  • HY-N0171B
    Beta-Sitosterol (purity>75%) 83-46-5 ≥98.0%
    Beta-Sitosterol (purity>75%) is a phytosterol with oral activity. Beta-Sitosterol (purity>75%) interferes with a variety of cell signaling pathways, including the cell cycle, apoptosis and cell proliferation. Beta-Sitosterol (purity>75%) has anti-inflammatory, antioxidant, and antitumor activities.
    Beta-Sitosterol (purity>75%)
  • HY-N12060
    Ginkgo biloba extract 90045-36-6
    Ginkgo biloba extract a natural product isolated from Ginkgo biloba, and can be used for Atherosclerosis and cardiovascular study.
    Ginkgo biloba extract
  • HY-N7079A
    Sodium erythorbate 6381-77-7 ≥98.0%
    Sodium erythorbate is an orally active sodium salt form of isoascorbic acid. Sodium erythorbate improves the radiation resistance of Listeria monocytogenes. Sodium erythorbate can react with free radicals and reduce oxidative damage. Sodium erythorbate has weak antiscorbic activity. Sodium erythorbate can prevent oxidative discoloration in meat products.
    Sodium erythorbate
  • HY-N7395A
    Cyclic ADP-​ribose ammonium ≥99.0%
    Cyclic ADP-ribose ammonium (cADPR ammonium) is a potent second messenger for calcium mobilization that is synthesized from NAD+ by an ADP-ribosyl cyclase. Cyclic ADP-ribose ammonium increases cytosolic calcium mainly by Ryanodine receptor-mediated release from endoplasmic reticulum and also by extracellular influx through the opening of TRPM2 channels.
    Cyclic ADP-​ribose ammonium
  • HY-P0316A
    TP508 TFA 99.44%
    TP508 TFA is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues.
    TP508 TFA
  • HY-P10655
    Caloxin 1C2 98.86%
    Caloxin 1C2 is a specific PMCA (plasma-membrane Ca2+-ATPases) inhibitor. Caloxin 1C2 is selective for PMCA4 over PMCA1, 2 and 3. The Ki values of Caloxin 1C2 are 2.3 μM for PMCA4 and 21 μM for PMCA1. Caloxin 1C2 dose not cause any significant effects on total Ca2+ transfer. Caloxin 1C2 affects coronary contractility.
    Caloxin 1C2
  • HY-P1339B
    Orexin B, human acetate 99.64%
    Orexin B, human acetate is the acetate form of Orexin B, human (HY-P1339). Orexin B, human acetate is the agonist for Orexin Receptor, with Ki of 420 nM and 36 nM for OX1 and OX2. Orexin B, human acetate participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine.
    Orexin B, human acetate
  • HY-P1741A
    Fibrinogen-Binding Peptide TFA 99.32%
    Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin.
    Fibrinogen-Binding Peptide TFA
  • HY-P1815A
    C-Type Natriuretic Peptide (1-53), human TFA 99.00%
    C-Type Natriuretic Peptide (1-53), human TFA is the 1-53 fragment of C-Type Natriuretic Peptide. C-Type Natriuretic Peptide TFA is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone.
    C-Type Natriuretic Peptide (1-53), human TFA
  • HY-U00186
    K134 189362-06-9 99.84%
    K134 is a phosphodiesterase 3 (PDE3) inhibitor. The IC50s of K134 toward PDE3A, PDE3B, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 µM, respectively.
    K134
  • HY-100607A
    Landiolol hydrochloride 144481-98-1 ≥98.0%
    Landiolol (ONO1101) hydrochloride is a highly selective, ultra-short-acting competitive inhibitor of β1 adrenergic receptors. Landiolol hydrochloride specifically blocks cardiac β1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol hydrochloride inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol hydrochloride has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol hydrochloride can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury.
    Landiolol hydrochloride
  • HY-101374A
    AGN 192403 hydrochloride 1021868-90-5 ≥99.0%
    AGN 192403 (BRD4780) hydrochloride is an I1-Imidazoline receptor antagonist for cardiovascular and neurological research.
    AGN 192403 hydrochloride
  • HY-101436A
    Sematilide hydrochloride 101526-62-9 99.33%
    Sematilide hydrochloride (CK-1752 hydrochloride) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K+ current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent.
    Sematilide hydrochloride
  • HY-108556A
    RWJ-56110 dihydrochloride 2387505-58-8 99.54%
    RWJ-56110 dihydrochloride is a potent, selective, peptide-mimetic inhibitor of PAR-1 activation and internalization (binding IC50=0.44 uM) and shows no effect on PAR-2, PAR-3, or PAR-4. RWJ-56110 dihydrochloride inhibits the aggregation of human platelets induced by both SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM), quite selective relative to U46619 (HY-108566). RWJ-56110 dihydrochloride blocks angiogenesis and blocks the formation of new vessels in vivo. RWJ-56110 dihydrochloride induces cell apoptosis.
    RWJ-56110 dihydrochloride
  • HY-111326A
    Naphazoline nitrate 5144-52-5 ≥98.0%
    Naphazoline (Naphthazoline) nitrate is an α-adrenergic receptor agonist. Naphazoline nitrate reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline nitrate reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline nitrate can be used for non-bacterial conjunctivitis research.
    Naphazoline nitrate
  • HY-123268A
    Ro 363 hydrochloride 250580-70-2
    Ro 363 hydrochloride, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. Ro 363 hydrochloride is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility.
    Ro 363 hydrochloride
  • HY-136182A
    YM-244769 838819-70-8 98.04%
    YM-244769 is a potent, selective and orally active Na+/Ca2+ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice.
    YM-244769
  • HY-N0666S1
    L-Aspartic acid-13C4,15N 202468-27-7 ≥98.0%
    L-Aspartic acid-13C4,15N is the 13C-labeled and 15N-labeled L-Aspartic acid. L-Aspartic acid is is an amino acid, shown to be a suitable proagent for colon-specific agent deliverly.
    L-Aspartic acid-13C4,15N
  • HY-N0666S2
    DL-Aspartic acid-d3 14341-75-4 99.56%
    DL-Aspartic acid-d3 is the deuterium labeled L-Aspartic acid. L-Aspartic acid is is an amino acid, shown to be a suitable proagent for colon-specific agent deliverly.
    DL-Aspartic acid-d3
Cat. No. Product Name / Synonyms Application Reactivity